About shattuck labs inc - STTK
Shattuck Labs, Inc. is a biotechnology company, which engages in the research and development of potential treatments for inflammatory and immune-mediated diseases. It focuses on developing a potential first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company was founded by Josiah C. Hornblower and Taylor Schreiber in 2016 and is headquartered in Austin, TX.
STTK At a Glance
Shattuck Labs, Inc.
500 West 5th Street
Austin, Texas 78701
| Phone | 1-512-900-4690 | Revenue | 5.72M | |
| Industry | Biotechnology | Net Income | -75,410,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 245.263% | |
| Fiscal Year-end | 12 / 2025 | Employees | 44 | |
| View SEC Filings |
STTK Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 10.735 |
| Price to Book Ratio | 0.725 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.107 |
| Enterprise Value to Sales | -1.427 |
| Total Debt to Enterprise Value | -0.417 |
STTK Efficiency
| Revenue/Employee | 130,022.727 |
| Income Per Employee | -1,713,863.636 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.045 |
STTK Liquidity
| Current Ratio | 8.884 |
| Quick Ratio | 8.884 |
| Cash Ratio | 8.185 |
STTK Profitability
| Gross Margin | 33.071 |
| Operating Margin | -1,404.387 |
| Pretax Margin | -1,318.126 |
| Net Margin | -1,318.126 |
| Return on Assets | -59.895 |
| Return on Equity | -67.231 |
| Return on Total Capital | -90.82 |
| Return on Invested Capital | -65.505 |
STTK Capital Structure
| Total Debt to Total Equity | 4.277 |
| Total Debt to Total Capital | 4.102 |
| Total Debt to Total Assets | 3.692 |
| Long-Term Debt to Equity | 3.147 |
| Long-Term Debt to Total Capital | 3.018 |